Trending NewsTrending NewsNASDAQ:BBNX Beta Bionics (BBNX) Stock Price, News & Analysis $20.24 -0.29 (-1.39%) As of 10:08 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Beta Bionics Stock (NASDAQ:BBNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beta Bionics alerts:Sign Up Key Stats Today's Range$20.50▼$20.6850-Day Range$12.83▼$22.8152-Week Range$8.80▼$32.71Volume21,979 shsAverage Volume1.19 million shsMarket Capitalization$910.37 millionP/E RatioN/ADividend YieldN/APrice Target$22.91Consensus RatingModerate Buy Company Overview Beta Bionics, Inc. is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input. The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes. The system combines an insulin pump, dosing-control software and a compatible continuous glucose monitor, and is designed to reduce the need for users to calculate insulin doses manually. Beta Bionics also develops related technologies intended to support automated diabetes care. The company was founded by Ed Damiano, an engineering professor and researcher whose work on automated insulin delivery helped lead to the development of the iLet system. Beta Bionics is based in the United States and initially serves the U.S. diabetes-care market through its commercialized iLet product.AI Generated. May Contain Errors. Read More Beta Bionics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreBBNX MarketRank™: Beta Bionics scored higher than 29% of companies evaluated by MarketBeat, and ranked 799th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingBeta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on no strong buy ratings, 8 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialBeta Bionics has a consensus price target of $22.91, representing about 11.6% upside from its current price of $20.52.Amount of Analyst CoverageBeta Bionics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beta Bionics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beta Bionics are expected to decrease in the coming year, from ($2.06) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beta Bionics is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beta Bionics is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeta Bionics has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.92% of the float of Beta Bionics has been sold short.Short Interest Ratio / Days to CoverBeta Bionics has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Beta Bionics has recently increased by 12.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeta Bionics does not currently pay a dividend.Dividend GrowthBeta Bionics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentBeta Bionics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 50 news articles for Beta Bionics this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for BBNX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,983,398.00 in company stock.Percentage Held by Insiders5.30% of the stock of Beta Bionics is held by insiders.Percentage Held by InstitutionsBeta Bionics has minimal institutional ownership at this time.Read more about Beta Bionics' insider trading history. Receive BBNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBNX Stock News HeadlinesBeta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 20262 hours ago | globenewswire.comBeta Bionics Legal Alert: Beta Bionics (BBNX) Investors who Lost Money are Notified of the Upcoming Deadline in the Ongoing Securities Fraud Class Action2 hours ago | prnewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 29 at 1:00 AM | Base Camp Trading (Ad)BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud LawsuitSeptember 28 at 6:05 PM | prnewswire.comBBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact Levi & KorsinskySeptember 28 at 10:22 AM | globenewswire.comInsider Selling: Beta Bionics (NASDAQ:BBNX) Director Sells 6,430 SharesSeptember 24, 2026 | insidertrades.comMike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) StockSeptember 18, 2026 | insidertrades.comBeta Bionics (NASDAQ:BBNX) Insider Sells 4,221 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines BBNX Stock Analysis - Frequently Asked Questions How have BBNX shares performed this year? Beta Bionics' stock was trading at $30.47 at the beginning of the year. Since then, BBNX shares have decreased by 32.7% and is now trading at $20.52. How were Beta Bionics' earnings last quarter? Beta Bionics, Inc. (NASDAQ:BBNX) posted its earnings results on Wednesday, July, 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company earned $32.01 million during the quarter. Beta Bionics had a negative trailing twelve-month return on equity of 26.30% and a negative net margin of 61.31%. Read the conference call transcript. When did Beta Bionics IPO? Beta Bionics (BBNX) raised $198 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at $16.00-$17.00 per share. How do I buy shares of Beta Bionics? Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2026Today9/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BBNX's financial health is in the Green zone, according to TradeSmith. BBNX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBNX Previous SymbolNASDAQ:BBNX CIK1674632 Webwww.betabionics.com Phone(949) 427-7785FaxN/AEmployees423Year Founded2015Price Target and Rating Average Price Target for Beta Bionics$22.91 High Price Target$32.00 Low Price Target$16.00 Potential Upside/Downside+11.0%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.20 million Net Margins-61.31% Pretax Margin-61.31% Return on Equity-26.30% Return on Assets-23.25% Debt Debt-to-Equity RatioN/A Current Ratio8.88 Quick Ratio7.96 Sales & Book Value Annual Sales$100.25 million Price / Sales9.27 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book3.16Miscellaneous Outstanding Shares44,990,000Free Float42,606,000Market Cap$928.82 million OptionableN/A Beta3.37 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BBNX) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
